The IGF Axis Involvement in Immune Tumor Microenvironment in Ovarian Cancer and Its Clinical Significance


The aim of this study is to evaluate the insulin-like growth factor (IGF) axis involvement in the immune tumor microenvironment in ovarian cancer.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 2021


  • Other: Biopsy
    • Biopsy taken during surgical procedure

Arms, Groups and Cohorts

  • Ovarian cancer patients
    • Biopsy will be taken from ovarian cancer patients and sent to laboratory for analysis

Clinical Trial Outcome Measures

Primary Measures

  • Involvement of IGF Axis in Ovarian Cancer
    • Time Frame: Two years
    • Ovarian cancer specimens taken during surgical procedures will be evaluated and analyzed by flow cytometry assays to determine the involvement of the IGF axis in the immune tumor microenvironment in ovarian cancer

Participating in This Clinical Trial

Inclusion Criteria

  • Women diagnosed with epithelium ovarian cancer who have undergone surgery

Exclusion Criteria

  • Pregnant women

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hillel Yaffe Medical Center
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Ilan Bruchim, MD, Principal Investigator, Hillel Yaffe Medical Center
  • Overall Contact(s)
    • Hagit Stolz, DVM, 972-4-7744335,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.